Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion

Ophthalmology

Volumn 107, Issue 8, 2000, Pages 1588-1592

  Pianka, Pazit ^a   Almog, Yehoshua ^a   Man, Oran ^a   Goldstein, Michaela ^a   Sela, Ben Ami ^b   Loewenstein, Anat ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTINE;

ADULT; ARTICLE; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; FEMALE; HOMOCYSTINURIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; ISCHEMIC OPTIC NEUROPATHY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR;

AGED; ARTERITIS; CASE-CONTROL STUDIES; FEMALE; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; MIDDLE AGED; OPTIC NEUROPATHY, ISCHEMIC; PREVALENCE; RETINAL ARTERY OCCLUSION; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0033773830     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(00)00181-0     Document Type: Article

References (56)

1. Hyperhomocystinemia: An independent risk factor for vascular disease
2. Hyperhomocystinemia as a risk factor for deep-vein thrombosis
3. Homocystine and cardiovascular disease
4. A quantitative assessment of plasma homocystine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
5. Homocystine and thrombotic disease
6. Plasma homocystine levels and mortality in patients with coronary artery disease
7. Plasma homocystine as a risk factor for vascular disease. The European Concerted Action Project
8. Vascular pathology of homocystinemia: Implications for the pathogenesis of arteriosclerosis
9. Homocystine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase
10. Adverse vascular effects of homocystine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen
11. Metabolism of homocystine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocystine levels
12. Homocystine and hemostasis: Pathogenic mechanisms predisposing to thrombosis
13. Thermolabile methylenetetrahydrofolate reductase: An inherited risk factor for coronary artery disease
14. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase
15. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation
16. The mutation Ala677->Val in the methylene tetrahydrofolate reductase gene: A risk factor for arterial disease and venous thrombosis
17. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese
18. Homocystine and risk of premature coronary heart disease. Evidence for a common gene mutation
19. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease
20. A quantitative assessment of plasma homocystine as a risk. Factor for vascular disease. Probable benefits of increasing folic acid intakes
21. Plasma homocystine before and after methionine loading with regard to age, gender, and menopausal status
22. Hyperhomocystinemia and traditional cardiovascular disease risk factor in endstage renal disease patients on dialysis: A case-control study
23. Changes in plasma methionine and total homocystine levels in patients recetving methotrexate infusions
24. Monitoring cobalamin inactivation during nitrous oxide anesthesia by determination of homocystine and folate in plasma and urine
25. Colestipol plus niacin therapy elevates plasma homocystine levels
26. Vitamin status and intake as primary determinates of homocystinemia in an elderly population
27. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy
28. Mechanisms of retinal arterial occlusive disease in African American and Caucasian patients
29. Protein S deficiency and bilateral branch retinal artery occlusion
30. Retinal arterial occlusion associated with resistance to activated protein C
31. Arterial vascular occlusion associated with factor V Leiden gene mutation
32. Retinal arterial occlusion in a child with factor V Leiden and thermolabile methylene tetrahydrofolate reductase mutations
33. Hyperhomocystinemia in retinal artery and retinal vein occlusion
34. Risk factors for branch retinal vein occlusion The Eye Disease Case-control Study Group
35. The Central Vein Occlusion Study. Central Vein Occlusion Study Group
36. Antiphospholipid antibodies in retinal vascular occlusions. A prospective study of 75 patients
37. Elevated erythrocyte aggregation in patients with central retinal vein occlusion and without conventional risk factors
38. Ophthalmic manifestations of neonatal protein C deficiency
39. Factor V Leiden, activated protein C resistance, and retinal vein occlusion Retina
40. Retinal vein occlusion and transient monocular visual loss associated with hyperhomocystinemia
41. Bilateral central retinal vein occlusion associated with 5,10-methylenetetrahydrofolate reductase mutation
42. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion
43. Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation
44. Determination of plasma homocystine by high-performance liquid chromatography with fluorescence detection
45. Quantitation of total homocystine, total cysteine, and methionine in normal serum and urine using capillary gas chromatography-mass spectrometry
46. Recommended approaches for the laboratory measurement of homocystine in the diagnosis and monitoring of patients with hyperhomocysteinaemia
47. Biological variability and reference intervals for total plasma homocystine
48. Homocystine and other thiols in plasma and urine: Automated determination and sample stability
49. Homocystine metabolism
50. Prospective blinded study of the relationship between plasma homocystine and progression of symptomatic peripheral arterial disease
51. The effect Of folic acid fortification on plasma folate and total homocystine concentrations
52. Low-dose folic acid supplementation decreases plasma homocystine concentrations: A randomized trial
53. Lowering of homocystine concentrations in elderly men and women
54. Reduction of homocystine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12
55. Normohomocystinaemia and vitamin-treated hyperhomocystinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study